Clinical trial · Observational
Role of Serum Regucalcin in Diagnosis of Hepatocellular Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Although the diagnosis and therapy of HCC have being improved, the poor prognosis still remains. To reduce the mortality and improve the effectiveness of diagnosis and therapy, it is important to detect the protein biomarkers which are associated with HCC tumor progression and may be useful as potential diagnosis or therapeutic targets. SMP30 (senescence marker protein 30)(serum regucalcin), which we have previously identified from Guangxi HCC cDNA expression library by the SEREX approach, is one of the hepatocellular carcinoma associated antigens \[4\] Serum antibody response to SMP30 in various patients using the methods of Western-blot and ELISA and showed that antibody to SMP30 existed mainly in HCC patients (39.8%), especially in the one with alpha-fetoprotein (AFP) negative
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Role of Serum Regucalcin in Diagnosis of HCC | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| serum regucalcin antibody | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- patients with HCC
- interventionNames
- Diagnostic Test: serum regucalcin antibody
- label
- patients with hepatitis C Ab positive
- interventionNames
- Diagnostic Test: serum regucalcin antibody
- label
- patients with hepatitis C Ab negative
- interventionNames
- Diagnostic Test: serum regucalcin antibody
Primary outcomes (1)
- measure
- serum regucalcin in HCC patients
- timeFrame
- 1-12-2016 to 1-12-2017
- description
- This work aims to assess serum regucalcin antibodies level using ELISA in HCC patients to: * evaluate its potential role as biomarker in diagnosis. * evaluate potential associations of the presence of serum regucalcin antibody with HCC patients' clinico-epidemiological parameters.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Newly diagnosed cases of HCC (be based on NCCN guidelines triphasic CT and AFP or liver biopsy) 2. Adult patients 3. Both genders are eligible. 4. Informed consent obtained from subject or subject's legal representative Exclusion Criteria: 1. Patient with other malignancies. 2. Patients with advanced comorbidities except for renal failure. 3. Prior chemotherapy
References
Publications (0)
Data not yet available